Personalized Vaccine for Advanced Ovarian Cancer Offers Promising Results in Pilot Study

Personalized Vaccine for Advanced Ovarian Cancer Offers Promising Results in Pilot Study
A personalized vaccine targeted to a patient’s own tumor cells yielded promising results in patients with recurrent advanced ovarian cancer, a Phase 1 pilot trial shows. The vaccine was safe, capable of triggering a broad anti-tumor immune response, and significantly delayed disease progression in patients responding to the therapy. The study “Personalized cancer vaccine effectively mobilizes antitumor T cell immunity in ovarian cancer” was published in the journal Science Translational Medicine. The new immunotherapy is a personalized vaccine made from the patient's own immune cells, namely dendritic cells, stimulated to target a tumor. Most cancer vaccines are designed to attack a specific known target, for instance, a receptor at the cell surface that is frequently present in that type of tumor. But even for the same type of cancer, each patient’s tumor has a unique set of mutations and looks different to the immune system. The new approach followed by the researchers creates a vaccine personalized for each patient, taking advantage of the body's natural anti-tumor immunity brought about by T-cells. From each patient, researchers collected white blood cells that then were grown
Subscribe or to access all post and page content.